Intervention Review

You have free access to this content

Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis

  1. Xiaomei Chen1,†,
  2. Ming Yang2,‡,
  3. Yan Cheng1,
  4. Guan J Liu3,
  5. Min Zhang1,*

Editorial Group: Cochrane Skin Group

Published Online: 23 OCT 2013

Assessed as up-to-date: 8 AUG 2013

DOI: 10.1002/14651858.CD009481.pub2


How to Cite

Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD009481. DOI: 10.1002/14651858.CD009481.pub2.

Author Information

  1. 1

    West China Hospital, Sichuan University, Department of Dermatology & Venereology, Chengdu, Sichuan, China

  2. 2

    West China Hospital, Sichuan University, Center of Geriatrics and Gerontology, Chengdu, Sichuan, China

  3. 3

    West China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, Chengdu, Sichuan, China

  1. ❖ Joint first author

  2. ✢ Joint first author

*Min Zhang, Department of Dermatology & Venereology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. hxlily@163.com. lily666@medmail.com.cn.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 23 OCT 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram
[Figure 2]
Figure 2. 'Risk of bias' summary: Review authors' judgements about each 'Risk of bias' item for each included study
[Figure 3]
Figure 3. 'Risk of bias' graph: Review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies
[Analysis 1.1]
Analysis 1.1. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 1 PASI 75.
[Analysis 1.2]
Analysis 1.2. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 2 PASI 75 (ITT analysis).
[Analysis 1.3]
Analysis 1.3. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 3 Withdrawals due to side-effects.
[Analysis 1.4]
Analysis 1.4. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 4 Withdrawals due to side-effects (ITT analysis).
[Analysis 1.5]
Analysis 1.5. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 5 Clearance rate.
[Analysis 1.6]
Analysis 1.6. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 6 Clearance rate (ITT analysis).
[Analysis 1.7]
Analysis 1.7. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 7 Clearance lasting 6 months.
[Analysis 1.8]
Analysis 1.8. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 8 Time to PASI 75.
[Analysis 1.9]
Analysis 1.9. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 9 Relapse rate at 6 months after treatment completion.
[Analysis 1.10]
Analysis 1.10. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 10 Withdrawals due to poor response.
[Analysis 1.11]
Analysis 1.11. Comparison 1 NB-UVB versus oral PUVA in CPP, Outcome 11 Adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 NB-UVB versus bath PUVA in CPP, Outcome 1 Clearance rate.
[Analysis 2.2]
Analysis 2.2. Comparison 2 NB-UVB versus bath PUVA in CPP, Outcome 2 Clearance rate (ITT analysis).
[Analysis 2.3]
Analysis 2.3. Comparison 2 NB-UVB versus bath PUVA in CPP, Outcome 3 PASI score reduction.
[Analysis 2.4]
Analysis 2.4. Comparison 2 NB-UVB versus bath PUVA in CPP, Outcome 4 Adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 NB-UVB versus topical PUVA in PPP, Outcome 1 Clearance rate.
[Analysis 3.2]
Analysis 3.2. Comparison 3 NB-UVB versus topical PUVA in PPP, Outcome 2 Clearance rate (ITT analysis).
[Analysis 3.3]
Analysis 3.3. Comparison 3 NB-UVB versus topical PUVA in PPP, Outcome 3 Relapse at 9 weeks after treatment completion.
[Analysis 3.4]
Analysis 3.4. Comparison 3 NB-UVB versus topical PUVA in PPP, Outcome 4 Marked improvement.
[Analysis 3.5]
Analysis 3.5. Comparison 3 NB-UVB versus topical PUVA in PPP, Outcome 5 Adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 1 PASI.
[Analysis 4.2]
Analysis 4.2. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 2 PASI 75 (ITT analysis).
[Analysis 4.3]
Analysis 4.3. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 3 Clearance rate.
[Analysis 4.4]
Analysis 4.4. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 4 Clearance rate (ITT analysis).
[Analysis 4.5]
Analysis 4.5. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 5 Relapse at 6 months after treatment completion.
[Analysis 4.6]
Analysis 4.6. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 6 Clinical improvement.
[Analysis 4.7]
Analysis 4.7. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 7 Tolerability assessed as good or very good by observers (ITT analysis).
[Analysis 4.8]
Analysis 4.8. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 8 Tolerability assessed as good or very good by participants (ITT analysis).
[Analysis 4.9]
Analysis 4.9. Comparison 4 NB-UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 9 Adverse events.
[Analysis 5.1]
Analysis 5.1. Comparison 5 NB-UVB versus selective BB-UVB in CPP, Outcome 1 Withdrawal due to side-effects.
[Analysis 5.2]
Analysis 5.2. Comparison 5 NB-UVB versus selective BB-UVB in CPP, Outcome 2 Withdrawals due to side-effects (ITT analysis).
[Analysis 5.3]
Analysis 5.3. Comparison 5 NB-UVB versus selective BB-UVB in CPP, Outcome 3 Clearance rate.
[Analysis 5.4]
Analysis 5.4. Comparison 5 NB-UVB versus selective BB-UVB in CPP, Outcome 4 Clearance rate (ITT analysis).
[Analysis 5.5]
Analysis 5.5. Comparison 5 NB-UVB versus selective BB-UVB in CPP, Outcome 5 Clearance lasting 6 months.
[Analysis 5.6]
Analysis 5.6. Comparison 5 NB-UVB versus selective BB-UVB in CPP, Outcome 6 Adverse events.
[Analysis 6.1]
Analysis 6.1. Comparison 6 NB-UVB versus conventional BB-UVB in different types of psoriasis, Outcome 1 Cumulative UV dose during the study.
[Analysis 7.1]
Analysis 7.1. Comparison 7 NB-UVB plus dithranol versus conventional BB-UVB plus dithranol in different types of psoriasis, Outcome 1 Cumulative UV dose during the study.